Galera Therapeutics, Inc. (“Galera”) (OTC: GRTX), a clinical-stage biopharmaceutical company focused on advancing a pan-NOS inhibitor through clinical development for patients with the hardest-to-treat forms of advanced breast cancer, and Obsidian Therapeutics, Inc. (“Obsidian”), a privately-held clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocyte, (“TIL”), cell therapies, announce that they have entered into a definitive merger agreement to combine in an all-stock transaction. Upon completion of the transaction, the combined company plans to operate under the name Obsidian Therapeutics, Inc. and will apply to trade on Nasdaq under the ticker symbol “OBX.”
Read the full article: Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350M Concurrent Private Placement //
Source: https://www.businesswire.com/news/home/20260414356791/en/Obsidian-Therapeutics-and-Galera-Therapeutics-Announce-Merger-Agreement-and-%24350-Million-Concurrent-Private-Placement